Question Bank › The feared thing keeps not happening

The feared thing keeps not happening

The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i

Calls Tested
994
Answered YES
93
Hit Rate
9.4%
rare by design

Pacific Premier Bancorp, Inc. (PPBI) — this company's answers

NO on the Q1 2024 call 2024-04-24 C+
The model's full reasoning — Q1 2024 call → NO我们根据指令,只使用提供的电话会议记录,判断是否存在一个具体的、公司特定的负面担忧,并且管理层是否用已经观察到的业务证据来反驳这一担忧。 首先,寻找公司特定的担忧。在电话会议中,分析师和公司管理层提到了哪些担忧? - 关于贷款需求:管理层提到“贷款需求相对温和”,“竞争加剧”,但这是行业普遍现象。 - 关于存款外流:管理层提到“存款流入继续主要流向货币市场基金、储蓄和零售存单”,但非计息存款增加了6500万美元,总存款增加了1.92亿美元。管理层还提到“我们预计本季度存款流动可能因季节性因素而逆转”,但这是预期,不是担忧。 - 关于资产质量:管理层提到非performing assets增加了3900万美元,主要是由于一个特定的多元化商业银行关系。管理层说“该借款人目前所有付款都是当前的,我们期末总贷款拖欠率仅为0.09%。” 这似乎是对资产质量担忧的回应,但担忧是具体的吗?分析师是否在追问?在问答环节,分析师Chris McGratty问到了资产负债表和贷款增长,但没有直接问资产质量。分析师Matthew Clark问到了NIM和存款成本,也没有直接问资产质量。分析师Andrew Terrell问到了FHLB和存款季节性,也没有。分析师Gary Tenner问到了竞争环境,分析师David Feaster问到了贷款销售和资产质量,但问题比较宽泛。 关键点:是否有分析师明确表达了对某个具体负面结果的担忧?例如,担心贷款组合会继续收缩?担心存款会流失?担心资产质量恶化?在问答中,分析师们主要问的是NIM、存款成本、贷款增长、资本回报等,但并没有明确说“我们担心X会发生”这样的表述。管理层在开场白中提到了“我们继续执行高水平的风险管理”,“我们保持了对审慎风险管理的承诺”,但这是常规表述。 再仔细看:管理层提到“我们开始看到新的贷款机会略有增加,并谨慎乐观地认为我们能够在今年增加高质量的关系贷款。” 这是对未来的展望,不是对担忧的反驳。 关于资产质量,管理层主动提到了那个特定的借款人,并说“该借款人目前所有付款都是当前的”,这似乎是在回应可能存在的担忧,但分析师并没有在问答中追问这个问题。管理层在开场白中主动提及,可能因为这是本季度的重要事件,但分析师没有直接问。 有没有分析师在问题中表达了对特定结果的担忧?例如,Matthew Clark问到了“swap income running off more so in 4Q”,并问“what are the odds of maybe considering those securities loss trade, just to help mitigate that downdraft?” 这暗示了对未来NIM下降的担忧,但这是关于利率和swap的,不是公司特定的负面结果,而是行业普遍问题。 Chris McGratty问到了“balance sheet tweaking comments”,并问“does that mean we decline in loans for a little bit more and maybe grow in the back half?” 这暗示了对贷款下降的担忧,但管理层回答“我们期望逆转这种下降”,但这是预期,不是已经观察到的证据。 管理层在回答中提到了“我们确实看到非计息存款增加了6500万美元”,这是已经观察到的证据,但这是对存款流失担忧的反驳吗?分析师没有明确表达对存款流失的担忧,管理层自己提到了“我们预计本季度存款流动可能因季节性因素而逆转”,这是承认未来可能有问题,但这不是对担忧的反驳。 再考虑:是否有分析师明确说“我们担心X”?没有。所有问题都是询问性的,没有明确表达担忧。 管理层在开场白中提到了“我们继续执行高水平的风险管理”,“我们保持了对审慎风险管理的承诺”,但这是常规。 因此,没有看到分析师或管理层明确命名一个具体的、公司特定的负面担忧,并针对该担忧提供已经观察到的证据。管理层提到了一些积极数据,如存款增长、非计息存款增加,但这些都是对业绩的陈述,不是对担忧的反驳。 结论:没有符合条件的具体担忧和反驳。所以答案应为NO。

← Back to the full PPBI analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company — a worry that is live on this call, evident either because analysts keep probing it or because management itself names it as a concern others hold — AND does management push back on that worry by pointing to CURRENT, ALREADY-OBSERVED evidence from the business showing that the feared outcome is, so far, NOT materializing? Answer YES when BOTH halves come through in the transcript as one coherent dynamic, in whatever form fits the business: (1) A NAMED, COMPANY-SPECIFIC FEAR THAT IS LIVE NOW. The worry is concrete and attached to this company — for example: that demand will fall off after an unusually strong stretch; that a major customer, contract, or partner will shrink, leave, or not renew; that a competitor, new technology, or cheaper alternative will take the company's business; that a key product, franchise, or pricing level is about to erode; that recent growth is a one-time bulge that will reverse; or another identifiable adverse outcome the market has been bracing for. The fear must be visible on the call itself — analysts returning to it in their questions, or management acknowledging in its own words that this is what people are worried about — not merely a generic risk factor or ordinary caution. (2) MANAGEMENT ANSWERS WITH OBSERVED BEHAVIOR, NOT REASSURANCE. Management responds by citing things that have ALREADY HAPPENED or are happening now — customers renewing, reordering, or expanding when they were expected to leave; demand holding or growing through the period when a drop-off was predicted; the threatened product, customer, or pricing actually performing in the recent period; competitive losses that have not shown up in real accounts; the feared cliff period arriving and being cleared — described with enough concrete substance (who, what, how much, or compared to when) that the rebuttal rests on evidence from the business rather than on confidence, promises, arguments about why the fear is illogical, or projections that the future will be fine. Answer NO if no specific company-attached worry is visible on the call — a routinely healthy company fielding ordinary questions is not this. Answer NO if the fear is visible but management's response is mainly reassurance, optimism, plans, or forecasts without already-observed evidence against it. Answer NO if the evidence shows the feared outcome IS materializing and management is excusing, minimizing, or promising to fix it. Answer NO if the worry is only broad macro or industry-wide gloom with nothing specific to this company's own business. Answer NO if management concedes the fear is valid and pivots to a different story instead of countering it. Answer NO if the counter-evidence is only a single vague assertion (such as 'demand remains strong') with no concrete grounding in what has actually occurred. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
AVTR Avantor, Inc. Q2 2024 2024-07-26 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
GL Globe Life Inc. Q1 2024 2024-04-23 F
MNKD MannKind Corporation Q4 2023 2024-02-27 C
NICE NICE Ltd. Q4 2023 2024-02-22 B+
TYGO Tigo Energy, Inc. Q4 2023 2024-02-14 F
MET MetLife, Inc. Q4 2023 2024-02-01 B+
BBVA Banco Bilbao Vizcaya Argentaria, S.A. Q4 2023 2024-01-30 B+
TBLA Taboola.com Ltd. Q3 2023 2023-11-08 B+
GMED Globus Medical, Inc. Q3 2023 2023-11-07 B
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
MAC The Macerich Company Q3 2023 2023-10-31 D
LNTH Lantheus Holdings, Inc. Q2 2023 2023-08-03 C+
SITM SiTime Corporation Q2 2023 2023-08-02 C+
TREX Trex Company, Inc. Q2 2023 2023-07-31 B+
REYN Reynolds Consumer Products Inc. Q1 2023 2023-05-10 C
DOCN DigitalOcean Holdings, Inc. Q1 2023 2023-05-09 C+
ULCC Frontier Group Holdings, Inc. Q1 2023 2023-05-07 C+
AKR Acadia Realty Trust Q4 2022 2023-05-06 B+
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
EPR EPR Properties Q1 2023 2023-04-27 C+
MEDP Medpace Holdings, Inc. Q1 2023 2023-04-25 B+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
POOL Pool Corporation Q4 2022 2023-02-16 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
REGN Regeneron Pharmaceuticals, Inc. Q4 2022 2023-02-03 C
HBAN Huntington Bancshares Incorporated Q4 2022 2023-01-20 B
A Agilent Technologies, Inc. Q4 2022 2022-11-21 B+
PCTY Paylocity Holding Corporation Q1 2023 2022-11-05 A
TT Trane Technologies plc Q3 2022 2022-11-02 A
APOG Apogee Enterprises, Inc. Q2 2023 2022-09-20 A
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ZBRA Zebra Technologies Corporation Q2 2022 2022-08-02 C+
LIN Linde plc Q2 2022 2022-07-28 B+
SHW The Sherwin-Williams Company Q2 2022 2022-07-27 D
JBHT J.B. Hunt Transport Services, Inc. Q2 2022 2022-07-19 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
KFY Korn Ferry Q4 2022 2022-06-22 B
SE Sea Limited Q1 2022 2022-05-17 F
DCGO DocGo Inc. Q1 2022 2022-05-14 C
ZVIA Zevia PBC Q1 2022 2022-05-12 B
EGHT 8x8, Inc. Q4 2022 2022-05-10 C+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
ABNB Airbnb, Inc. Q1 2022 2022-05-03 B+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
BSX Boston Scientific Corporation Q1 2022 2022-04-27 B
CCK Crown Holdings, Inc. Q1 2022 2022-04-26 C+
FR First Industrial Realty Trust, Inc. Q1 2022 2022-04-21 A
SDIG Stronghold Digital Mining, Inc. Q3 2021 2021-11-30 F
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
HSY The Hershey Company Q3 2021 2021-10-28 C
PEP PepsiCo, Inc. Q3 2021 2021-10-05 B
GDS GDS Holdings Limited Q2 2021 2021-08-17 C+
PTVE Pactiv Evergreen Inc. Q2 2021 2021-08-08 C+
SPG Simon Property Group, Inc. Q2 2021 2021-08-02 B
GLW Corning Incorporated Q2 2021 2021-07-27 B+
DOV Dover Corporation Q2 2021 2021-07-20 B+
VLRS Controladora Vuela Compañía de Aviación, Q2 2021 2021-07-16 B+
MAR Marriott International, Inc. Q2 2018 2018-08-07 B
VALE Vale S.A. Q2 2018 2018-07-26 B
FICO Fair Isaac Corporation Q3 2018 2018-07-26 C+
ORAN Orange SA Q2 2018 2018-07-26 B
KIM Kimco Realty Corporation Q2 2018 2018-07-26 B+
TRUE TrueCar, Inc. Q1 2018 2018-05-08 C
TGNA TEGNA Inc. Q1 2018 2018-05-08 B+
CVS CVS Health Corporation Q1 2018 2018-05-02 B+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
MIDD The Middleby Corporation Q4 2017 2018-02-28 C
SBUX Starbucks Corporation Q1 2018 2018-01-26 C
AVT Avnet, Inc. Q2 2018 2018-01-25 B
GURE Gulf Resources, Inc. Q3 2017 2017-11-14 F
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
MKTX MarketAxess Holdings Inc. Q3 2017 2017-10-25 C+
PII Polaris Inc. Q3 2017 2017-10-24 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BCRX BioCryst Pharmaceuticals, Inc. Q1 2017 2017-05-07 B
ICFI ICF International, Inc. Q1 2017 2017-05-06 B+
CGNT Cognyte Software Ltd. Q4 2016 2017-03-09 D
BDC Belden Inc. Q4 2016 2017-02-02 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
SEM Select Medical Holdings Corporation Q1 2016 2016-05-06 C+
LPSN LivePerson, Inc. Q1 2016 2016-05-04 B
UVE Universal Insurance Holdings, Inc. Q1 2016 2016-05-03 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
VRTS Virtus Investment Partners, Inc. Q1 2016 2016-04-29 D
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
BX Blackstone Inc. Q1 2016 2016-04-21 B
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.

More from the question bank

Doors opening at the company's own gatesReporting the counterparty's growth as its oSecond proving already underwayNew normal declared and staffedBigger than they can carry aloneDemand arrived first, the company is growingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.